Folgen
Carlos E. Vigil, MD
Carlos E. Vigil, MD
Robert H. Lurie Comprehensive Cancer Center Northwestern University, Feinberg School of Medicine
Bestätigte E-Mail-Adresse bei northwestern.edu
Titel
Zitiert von
Zitiert von
Jahr
Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database
CS Vallejos, HL Gómez, WR Cruz, JA Pinto, RR Dyer, R Velarde, ...
Clinical breast cancer 10 (4), 294-300, 2010
2892010
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model
K Naqvi, G Garcia-Manero, S Sardesai, J Oh, CE Vigil, S Pierce, X Lei, ...
Journal of Clinical Oncology 29 (16), 2240-2246, 2011
1782011
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies …
ST Mahmood, S Agresta, CE Vigil, X Zhao, G Han, G D'Amato, CE Calitri, ...
International journal of cancer 129 (8), 1963-1969, 2011
1402011
Current progress in targeted therapy for colorectal cancer
J Ortega, CE Vigil, C Chodkiewicz
Cancer control 17 (1), 7-15, 2010
1112010
Myelodysplastic syndromes and autoimmune diseases—case series and review of literature
O Al Ustwani, LA Ford, SJN Sait, AMW Block, M Barcos, CE Vigil, ...
Leukemia research 37 (8), 894-899, 2013
872013
The Epstein-Barr virus (EBV) in T cell and NK cell lymphomas: time for a reassessment
AA Gru, BH Haverkos, AG Freud, J Hastings, NB Nowacki, C Barrionuevo, ...
Current hematologic malignancy reports 10, 456-467, 2015
802015
The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome
A McBride, S Houtmann, L Wilde, C Vigil, CM Eischen, M Kasner, ...
Frontiers in oncology 9, 192, 2019
452019
Clinical use of FLT3 inhibitors in acute myeloid leukemia
G Sutamtewagul, CE Vigil
OncoTargets and therapy, 7041-7052, 2018
412018
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients≥ 60 years old
N Gupta, A Miller, S Gandhi, LA Ford, CE Vigil, EA Griffiths, JE Thompson, ...
American journal of hematology 90 (7), 639-646, 2015
402015
Safety and efficacy of azacitidine in myelodysplastic syndromes
CE Vigil, T Martin-Santos, G Garcia-Manero
Drug Design, Development and Therapy, 221-229, 2010
382010
Interpretation of cytogenetic and molecular results in patients treated for CML
CE Vigil, EA Griffiths, ES Wang, M Wetzler
Blood reviews 25 (3), 139-146, 2011
342011
Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer
J Buleje, M Guevara‐Fujita, O Acosta, FDP Huaman, P Danos, A Murillo, ...
Molecular genetics & genomic medicine 5 (5), 481-494, 2017
262017
Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients
HL Gómez, CA Castañeda, CE Vigil, T Vidaurre, RG Velarde, WR Cruz, ...
Hematology/oncology and stem cell therapy 3 (3), 109-115, 2010
252010
Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas
CE Vigil, AA Chiappori, CA Williams, HH Shrager, BL Murray, DG Letson, ...
Journal of Clinical Oncology 26 (15_suppl), 10535-10535, 2008
252008
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
S de Botton, T Cluzeau, C Vigil, RJ Cook, P Rousselot, DA Rizzieri, ...
Blood advances 7 (9), 1858-1870, 2023
212023
Younger patients with newly diagnosed FLT3-mutant AML treated with crenolanib plus chemotherapy achieve adequate free crenolanib levels and durable remissions
AD Goldberg, CC Coombs, ES Wang, RB Walter, C Karanes, CE Vigil, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
212019
Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3-mutated AML
AD Goldberg, RH Collins, RM Stone, RB Walter, C Karanes, CE Vigil, ...
Blood 132, 1436, 2018
152018
Factores pronósticos en cáncer de mama, estadio clínico temprano (I-IIa) sometidos a cirugía como tratamiento de inicio.
M Carrasco, H Gómez, C Vigil
Carcinos 2 (3), 2013
152013
Early results from a biomarker-directed phase 2 trial of Sy-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid …
JG Jurcic, A Raza, G Vlad, EM Stein, M Roshal, DL Bixby, DF Boyer, ...
Blood 130, 2633, 2017
142017
Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer
HL Gómez, JA Pinto, M Olivera, T Vidaurre, FD Doimi, CE Vigil, ...
The Breast 20 (1), 39-45, 2011
132011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20